Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Jun 2

PMID 34063186

Citations 3

Authors

Nathalia Alves Araujo de Almeida

Camilla Rodrigues de Almeida Ribeiro

Jessica Vasques Raposo

Vanessa Salete de Paula

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has been shown to be highly effective in some types of cancer caused by viruses. Gene therapy involves insertion or modification of a therapeutic gene, to correct for inappropriate gene products that cause/may cause diseases. Both these types of therapy have been used as alternative ways to avoid cancers caused by oncoviruses. In this review, we summarize recent studies on immunotherapy and gene therapy including the topics of oncolytic immunotherapy, immune checkpoint inhibitors, gene replacement, antisense oligonucleotides, RNA interference, clustered regularly interspaced short palindromic repeats Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing, transcription activator-like effector nucleases (TALENs) and custom treatment for Epstein-Barr virus, human T-lymphotropic virus 1, hepatitis B virus, human papillomavirus, hepatitis C virus, herpesvirus associated with Kaposi's sarcoma, Merkel cell polyomavirus, and cytomegalovirus.

Citing Articles

In Vivo Fate of Cowpea Mosaic Virus In Situ Vaccine: Biodistribution and Clearance.

de Oliveira J, Chan S, Omole A, Agrawal V, Steinmetz N ACS Nano. 2022; 16(11):18315-18328.

PMID: 36264973 PMC: 9840517. DOI: 10.1021/acsnano.2c06143.

Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.

Vitiello G, Ferreira W, Cordeiro de Lima V, da Silva Medina T Front Immunol. 2021; 12:782852.

PMID: 34925363 PMC: 8674309. DOI: 10.3389/fimmu.2021.782852.

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.

Xie X, Lv J, Zhu W, Tian C, Li J, Liu J Transl Oncol. 2021; 15(1):101287.

PMID: 34808461 PMC: 8607272. DOI: 10.1016/j.tranon.2021.101287.

References

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Alexander R, Fang G, Rozowsky J, Snyder M, Gerstein M . Annotating non-coding regions of the genome. Nat Rev Genet. 2010; 11(8):559-71. DOI: 10.1038/nrg2814. View

Frenel J, Le Tourneau C, ONeil B, Ott P, Piha-Paul S, Gomez-Roca C . Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017; 35(36):4035-4041. DOI: 10.1200/JCO.2017.74.5471. View

Conway A, Mendel M, Kim K, McGovern K, Boyko A, Zhang L . Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets. Mol Ther. 2019; 27(4):866-877. PMC: 6453547. DOI: 10.1016/j.ymthe.2019.03.003. View

Broeders M, Herrero-Hernandez P, Ernst M, van der Ploeg A, Pijnappel W . Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. iScience. 2020; 23(1):100789. PMC: 6941877. DOI: 10.1016/j.isci.2019.100789. View

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

Wu Z, Chow K, Kuo T, Chang Y, Chao C . Latent membrane protein 1 of Epstein-Barr virus sensitizes cancer cells to cisplatin by enhancing NF-κB p50 homodimer formation and downregulating NAPA expression. Biochem Pharmacol. 2011; 82(12):1860-72. DOI: 10.1016/j.bcp.2011.09.010. View

Hall A, Alexander K . RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol. 2003; 77(10):6066-9. PMC: 154052. DOI: 10.1128/jvi.77.10.6066-6069.2003. View

10.

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S . Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4(9):e609-16. DOI: 10.1016/S2214-109X(16)30143-7. View

11.

Barrangou R, Doudna J . Applications of CRISPR technologies in research and beyond. Nat Biotechnol. 2016; 34(9):933-941. DOI: 10.1038/nbt.3659. View

12.

Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y . A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clin Cancer Res. 2019; 25(24):7363-7369. DOI: 10.1158/1078-0432.CCR-19-1680. View

13.

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

14.

Shankar S, Sreekumar A, Prasad D, Das A, Pillai M . Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design. Cancer Cell Int. 2018; 18:169. PMC: 6198504. DOI: 10.1186/s12935-018-0666-0. View

15.

Shankar S, Prasad D, Sanawar R, Das A, Pillai M . TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells. Sci Rep. 2017; 7(1):5500. PMC: 5511212. DOI: 10.1038/s41598-017-05696-0. View

16.

Kennedy E, Kornepati A, Mefferd A, Marshall J, Tsai K, Bogerd H . Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic. Methods. 2015; 91:82-86. PMC: 4684739. DOI: 10.1016/j.ymeth.2015.08.012. View

17.

Le Garff G, Samri A, Lambert-Niclot S, Even S, Lavole A, Cadranel J . Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS. 2017; 31(7):1048-1051. DOI: 10.1097/QAD.0000000000001429. View

18.

Hutvagner G, Zamore P . RNAi: nature abhors a double-strand. Curr Opin Genet Dev. 2002; 12(2):225-32. DOI: 10.1016/s0959-437x(02)00290-3. View

19.

Samimi M . Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. Am J Clin Dermatol. 2019; 20(3):391-407. DOI: 10.1007/s40257-019-00427-9. View

20.

Weber M, Fottner C . Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncol Res Treat. 2018; 41(5):306-312. DOI: 10.1159/000488996. View